Completed PHASE2/PHASE3 INTERVENTIONAL NCT00330707

Combined Use of BCG and Interferon Alpha in Bladder Cancer

A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer

Sponsor: National Medical Research Council (NMRC), Singapore

Conditions Carcinoma of Urinary Bladder, Superficial

Interventions Bacillus Calmette Guerin and interferon alpha

Updated 5 times since 2017 Last updated: Mar 2, 2011 Started: Oct 31, 1995 Completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00330707, this PHASE2/PHASE3 trial focuses on Carcinoma of Urinary Bladder, Superficial and remains completed. Sponsored by National Medical Research Council (NMRC), Singapore, it has been updated 5 times since 1995, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Oct 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Medical Research Council (NMRC), Singapore
National University Hospital, Singapore

Data source: National University Hospital, Singapore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore